Orexo appoints Henrik Juuel CFO
This article was originally published in Scrip
Emerging specialty pharma, Orexo, which has commercial operations in the US and R&D in Sweden developing proprietary drug delivery technologies, has appointed Henrik Juuel as executive vice-president and chief financial officer. Prior to joining the firm, Mr Juuel was CFO for NNE Pharmaplan and GN Resound. He succeeds Carl-Johan Blomberg, who is leaving the position after two-year tenure.